Developer docs
API playgroundTry for free, no card

Search company profiles

Inflammatix

Full company profile

uuid00005xk

Namestring
Inflammatix
Legal namestring
Inflammatix, Inc.
Websiteurl
inflammatix.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Inflammatix is a venture-backed molecular diagnostics company founded in 2016 that develops host-response tests reading the immune system to diagnose acute infections and predict sepsis severity. Its flagship product, the FDA-cleared TriVerity Test System, measures 29 host immune response mRNAs from a single blood sample and, using proprietary machine learning classifiers, returns three actionable scores (bacterial infection likelihood, viral infection likelihood, and risk of severe illness within 7 days) in approximately 30 minutes on the company's compact Myrna point-of-care instrument. The company targets hospital emergency departments, intensive care units, and adjacent public health and biodefense use cases, with a sales motion built on direct enterprise deployment to hospital systems. Co-founders Tim Sweeney (MD/PhD, CEO) and Purvesh Khatri (PhD, Chief Scientist) lead the company, supported by an executive bench staffed with veterans from Outset Medical, Intuitive Surgical, Becton Dickinson, and Abbott.

Inflammatix makes money primarily through sales of its proprietary TriVerity cartridges (consumables) and Myrna instruments to hospital laboratories and emergency departments, generating recurring revenue per test performed. Secondary revenue streams include licensing royalties on intellectual property exclusively licensed from Stanford University, and partnership and collaboration revenue from pharmaceutical and device companies using TriVerity for patient stratification in clinical trials. The company has secured significant non-dilutive capital from U.S. federal agencies including BARDA, NIH, and DARPA for diagnostic development. Total disclosed venture funding exceeds $194M across multiple rounds led by Khosla Ventures, D1 Capital Partners, and Northpond Ventures, with strategic investment from OSF Healthcare System. The firm holds ISO 13485:2016 certification, FDA Breakthrough Device Designation, and FDA 510(k) clearance, and operates from Sunnyvale, California with a wholly-owned subsidiary in Lisbon, Portugal.

Short descriptiontext

Inflammatix is a venture-backed molecular diagnostics company developing the FDA-cleared TriVerity Test System, a rapid host-response blood test that uses machine learning to distinguish bacterial from viral infections and predict sepsis severity for hospital emergency departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersSunnyvale, United States
HQ citystring
Sunnyvale
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
host response diagnostics, molecular diagnostic tests, sepsis diagnostics, immune response analysis, clinical decision support
Industry2 codes
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Surgical and Medical Instrument Manufacturing339112
SIC code3 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Laboratory Analytical Instruments3826
  • Surgical & Medical Instruments & Apparatus3841
Product category
Molecular Diagnostics
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Diagnostic Test Sales
TypeHardware Sales
Description

Sales of TriVerity test cartridges and Myrna instruments to hospital systems and laboratories. The test system generates recurring revenue through consumable cartridge sales for each test performed.

inflammatix.com
2Licensing Revenue
TypeLicensing Royalties
Description

Technology licensed from Stanford University with exclusive rights to core intellectual property for host response diagnostics.

inflammatix.com
3Partnership and Collaboration Revenue
TypeLicensing Royalties
Description

Collaborations with pharmaceutical and device companies to identify patients likely to respond to novel therapies, potentially generating milestone and royalty payments.

inflammatix.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1TriVerity
Description

First-in-class molecular blood test for diagnosing infection type (bacterial/viral) and predicting illness severity in patients with suspected acute infection or sepsis. Measures 29 host immune response mRNA markers and delivers results in approximately 30 minutes.

inflammatix.com
+1 more record
Core offering1 text field

Inflammatix develops and sells the TriVerity Test System, an FDA-cleared rapid blood test that measures 29 host immune response mRNA biomarkers and applies proprietary machine learning classifiers to deliver three actionable scores—likelihood of bacterial infection, viral infection, and severe illness within 7 days—in approximately 30 minutes from a single blood sample. The system consists of the Myrna point-of-care instrument and single-use TriVerity cartridges deployed in hospital emergency departments for triage of patients with suspected acute infection or sepsis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Validated in 1,222 patients across 22 sites with high sensitivity and specificity regardless of immune status or race
+4 more records
Product overview1 text field

Inflammatix offers a unified product portfolio centered on host-response molecular diagnostics. The flagship offering is the TriVerity Test System, which combines a disposable TriVerity Cartridge with the Myrna Instrument platform to deliver rapid infection diagnosis and severity prediction from a single blood test in approximately 30 minutes. The system uses a proprietary 29-mRNA host response panel interpreted by machine learning algorithms to distinguish bacterial from viral infections and predict ICU deterioration risk. In parallel, Inflammatix is developing an Endotypes Program for sepsis subtype classification to guide targeted therapies, though these pipeline products remain investigational and not yet commercially marketed.

Product and service3 records
1TriVerity Test System
CategoryCore Product
Description

FDA-cleared first-in-class molecular diagnostic test that measures 29 host immune response mRNAs to provide three actionable scores: likelihood of bacterial infection, likelihood of viral infection, and risk of severe illness within 7 days. Delivers results in approximately 30 minutes from a single blood sample for emergency department patients with suspected acute infection or sepsis.

2Myrna Instrument
CategoryPlatform
Description

Sample-to-answer isothermal point-of-care instrument platform that runs the TriVerity cartridge. Compact benchtop device (11.5-inch footprint) requiring no regular maintenance, with room-temperature cartridge storage, LIS connectivity options, and remote result notification capabilities.

3TriVerity Cartridge
CategoryConsumable
Description

Proprietary disposable cartridge containing the 29-mRNA host response assay. Single-use consumable for the TriVerity Test System, designed for room-temperature storage stability up to 9 months, generating recurring revenue per test performed.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-16
Description

Collaboration to deploy TriVerity host-response diagnostic test in response to hantavirus outbreak. TriVerity is being used to better understand early signatures of infection in individuals with high-risk exposures to hantavirus, providing rapid assessment of infection type and risk of deterioration.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Federal government partner providing funding support under contracts 75A50119C00034, 75A50119C00044, and 75A50122C00069 for development of TriVerity test system.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Federal research funding agency collaborating with Inflammatix on diagnostic development.

4DRIVe (Division of Research, Innovation, and Ventures)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

BARDA innovation initiative supporting development of diagnostics for emerging infectious diseases.

inflammatix.com
5DARPA
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Defense Advanced Research Projects Agency providing funding for early diagnostic technology development.

inflammatix.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

SUBtyping in SePsis And Critical illnEss consortium - collaborative of leading researchers and clinicians comparing different existing subtype classifiers for sepsis. Sponsored by Inflammatix, analyzing transcriptomic data from 7,000+ patient samples across 37 cohorts worldwide.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Develops AI-driven diagnostics for sepsis and acute care, including the Sepsis ImmunoScore. Competes with Inflammatix in applying machine learning to host-response and clinical data for early sepsis identification in hospital settings.

TypeBroad incumbent
Description

GeneXpert system is a leading rapid molecular POCT platform used in U.S. EDs for infectious disease testing. Overlaps with Inflammatix in the rapid-molecular-diagnostic category and competes for ED instrument placements and test-menu real estate.

TypeDirect peer
Description

Commercializes IntelliSep, a FDA-cleared rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample. Targets the same ED sepsis-triage workflow as TriVerity with a complementary host-immune-cell measurement approach.

TypeBroad incumbent
Description

Provides QIAstat-Dx molecular POCT systems and sample-prep technologies relevant to rapid infectious disease diagnostics. Adjacent incumbent in the molecular POCT category where Inflammatix's Myrna instrument also competes.

TypeBroad incumbent
Description

BioFire FilmArray panels are a dominant rapid molecular diagnostic for infectious disease in U.S. EDs. While pathogen-detection focused rather than host-response, BioFire is the most entrenched incumbent competing for ED test-menu slots and budgets.

TypeDirect peer
Description

Develops T2Bacteria and T2Candida direct-from-blood molecular diagnostics for sepsis-causing pathogens. Operates in the same ED/hospital sepsis-diagnosis segment with an alternative rapid-molecular approach to Inflammatix's host-response test.

TypeDirect peer
Description

Developer of SeptiCyte RAPID, a FDA-cleared host-response gene-expression test for sepsis diagnosis. Directly comparable to Inflammatix's TriVerity in mechanism (host mRNA signatures), clinical use case (ED/ICU sepsis triage), and customer base (hospital labs).

TypeBroad incumbent
Description

Offers a broad portfolio of hospital and ED diagnostics including Elecsys procalcitonin, cobas molecular systems, and emerging biomarker tests. A large incumbent competing for sepsis-triage test menus in the same hospital customer base.

TypeEmerging player
Description

Develops blood-based molecular and immune-response diagnostics, including interferon-score and immune-monitoring tests. Adjacent emerging player applying host-response biology to clinical diagnostics, comparable in technology category though currently focused on different indications.

10Abbott (Rapid Diagnostics / Alere)
TypeBroad incumbent
Description

i-STAT and Alinity instruments are widely deployed across U.S. EDs for rapid diagnostics including lactate and infectious disease markers. Competes with Inflammatix for ED bench-space real estate and test-menu decisions; Martín Vazquez previously led Abbott Rapid Dx.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration1 record

Each record includes

Title, Type, Description, Source

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles12 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds8 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors14 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Inflammatix

Molecular Diagnosticsinflammatix.com

Inflammatix is a venture-backed molecular diagnostics company developing the FDA-cleared TriVerity Test System, a rapid host-response blood test that uses machine learning to distinguish bacterial from viral infections and predict sepsis severity for hospital emergency departments.

What Inflammatix does

Inflammatix is a venture-backed molecular diagnostics company founded in 2016 that develops host-response tests reading the immune system to diagnose acute infections and predict sepsis severity. Its flagship product, the FDA-cleared TriVerity Test System, measures 29 host immune response mRNAs from a single blood sample and, using proprietary machine learning classifiers, returns three actionable scores (bacterial infection likelihood, viral infection likelihood, and risk of severe illness within 7 days) in approximately 30 minutes on the company's compact Myrna point-of-care instrument. The company targets hospital emergency departments, intensive care units, and adjacent public health and biodefense use cases, with a sales motion built on direct enterprise deployment to hospital systems. Co-founders Tim Sweeney (MD/PhD, CEO) and Purvesh Khatri (PhD, Chief Scientist) lead the company, supported by an executive bench staffed with veterans from Outset Medical, Intuitive Surgical, Becton Dickinson, and Abbott.

Inflammatix makes money primarily through sales of its proprietary TriVerity cartridges (consumables) and Myrna instruments to hospital laboratories and emergency departments, generating recurring revenue per test performed. Secondary revenue streams include licensing royalties on intellectual property exclusively licensed from Stanford University, and partnership and collaboration revenue from pharmaceutical and device companies using TriVerity for patient stratification in clinical trials. The company has secured significant non-dilutive capital from U.S. federal agencies including BARDA, NIH, and DARPA for diagnostic development. Total disclosed venture funding exceeds $194M across multiple rounds led by Khosla Ventures, D1 Capital Partners, and Northpond Ventures, with strategic investment from OSF Healthcare System. The firm holds ISO 13485:2016 certification, FDA Breakthrough Device Designation, and FDA 510(k) clearance, and operates from Sunnyvale, California with a wholly-owned subsidiary in Lisbon, Portugal.

Inflammatix firmographics

Firmographics
Name
Inflammatix
Legal name
Inflammatix, Inc.
Website
https://inflammatix.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
51–100 employees
Short description
Inflammatix is a venture-backed molecular diagnostics company developing the FDA-cleared TriVerity Test System, a rapid host-response blood test that uses machine learning to distinguish bacterial from viral infections and predict sepsis severity for hospital emergency departments.
Ownership category
akta.pro rank

Inflammatix industry classification

Industry
Product category
Molecular Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Surgical and Medical Instrument Manufacturing (339112)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHAOAA
Infectious Disease POCT (Respiratory, STI, HIV, Sepsis)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLACAGAA
Diagnostic & Triage Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Host response diagnostics
  • Molecular diagnostic tests
  • Sepsis diagnostics
  • Immune response analysis
  • Clinical decision support

Where Inflammatix is headquartered

Location

Headquarters

HQ city
Sunnyvale
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Inflammatix business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales

Revenue model

  1. Diagnostic Test Sales: Sales of TriVerity test cartridges and Myrna instruments to hospital systems and laboratories. The test system generates recurring revenue through consumable cartridge sales for each test performed.
  2. Licensing Revenue: Technology licensed from Stanford University with exclusive rights to core intellectual property for host response diagnostics.
  3. Partnership and Collaboration Revenue: Collaborations with pharmaceutical and device companies to identify patients likely to respond to novel therapies, potentially generating milestone and royalty payments.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Inflammatix product offering

Product offering

Core offering

Inflammatix develops and sells the TriVerity Test System, an FDA-cleared rapid blood test that measures 29 host immune response mRNA biomarkers and applies proprietary machine learning classifiers to deliver three actionable scores—likelihood of bacterial infection, viral infection, and severe illness within 7 days—in approximately 30 minutes from a single blood sample. The system consists of the Myrna point-of-care instrument and single-use TriVerity cartridges deployed in hospital emergency departments for triage of patients with suspected acute infection or sepsis.

Product overview

Inflammatix offers a unified product portfolio centered on host-response molecular diagnostics. The flagship offering is the TriVerity Test System, which combines a disposable TriVerity Cartridge with the Myrna Instrument platform to deliver rapid infection diagnosis and severity prediction from a single blood test in approximately 30 minutes. The system uses a proprietary 29-mRNA host response panel interpreted by machine learning algorithms to distinguish bacterial from viral infections and predict ICU deterioration risk. In parallel, Inflammatix is developing an Endotypes Program for sepsis subtype classification to guide targeted therapies, though these pipeline products remain investigational and not yet commercially marketed.

Differentiator

Problem solved

Functional benefit

Brands

  • TriVerity: First-in-class molecular blood test for diagnosing infection type (bacterial/viral) and predicting illness severity in patients with suspected acute infection or sepsis. Measures 29 host immune response mRNA markers and delivers results in approximately 30 minutes.
  • Myrna

Products and services

  • TriVerity Test System FDA-cleared first-in-class molecular diagnostic test that measures 29 host immune response mRNAs to provide three actionable scores: likelihood of bacterial infection, likelihood of viral infection, and risk of severe illness within 7 days. Delivers results in approximately 30 minutes from a single blood sample for emergency department patients with suspected acute infection or sepsis.
  • Myrna Instrument Sample-to-answer isothermal point-of-care instrument platform that runs the TriVerity cartridge. Compact benchtop device (11.5-inch footprint) requiring no regular maintenance, with room-temperature cartridge storage, LIS connectivity options, and remote result notification capabilities.
  • TriVerity Cartridge Proprietary disposable cartridge containing the 29-mRNA host response assay. Single-use consumable for the TriVerity Test System, designed for room-temperature storage stability up to 9 months, generating recurring revenue per test performed.

Quantifiable outcome

  • Validated in 1,222 patients across 22 sites with high sensitivity and specificity regardless of immune status or race
  • +4 more outcomes

Companies that use Inflammatix

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Inflammatix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature4 records

Inflammatix partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • University of Nebraska Medical CentercoreStrategic or Co-development Partner · 16 June 2026Collaboration to deploy TriVerity host-response diagnostic test in response to hantavirus outbreak. TriVerity is being used to better understand early signatures of infection in individuals with high-risk exposures to hantavirus, providing rapid assessment of infection type and risk of deterioration.
  • Biomedical Advanced Research and Development Authority (BARDA)coreStrategic or Co-development PartnerFederal government partner providing funding support under contracts 75A50119C00034, 75A50119C00044, and 75A50122C00069 for development of TriVerity test system.
  • National Institutes of Health (NIH)minorStrategic or Co-development PartnerFederal research funding agency collaborating with Inflammatix on diagnostic development.
  • DRIVe (Division of Research, Innovation, and Ventures)minorStrategic or Co-development PartnerBARDA innovation initiative supporting development of diagnostics for emerging infectious diseases.
  • DARPAminorStrategic or Co-development PartnerDefense Advanced Research Projects Agency providing funding for early diagnostic technology development.
  • SUBSPACE ConsortiumcoreStrategic or Co-development PartnerSUBtyping in SePsis And Critical illnEss consortium - collaborative of leading researchers and clinicians comparing different existing subtype classifiers for sepsis. Sponsored by Inflammatix, analyzing transcriptomic data from 7,000+ patient samples across 37 cohorts worldwide.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Inflammatix competitors and assessment

Company assessment

Emerging players

  • Prenosis: Develops AI-driven diagnostics for sepsis and acute care, including the Sepsis ImmunoScore. Competes with Inflammatix in applying machine learning to host-response and clinical data for early sepsis identification in hospital settings.
  • DxTerity Diagnostics: Develops blood-based molecular and immune-response diagnostics, including interferon-score and immune-monitoring tests. Adjacent emerging player applying host-response biology to clinical diagnostics, comparable in technology category though currently focused on different indications.

Broad incumbents

  • Cepheid (Danaher): GeneXpert system is a leading rapid molecular POCT platform used in U.S. EDs for infectious disease testing. Overlaps with Inflammatix in the rapid-molecular-diagnostic category and competes for ED instrument placements and test-menu real estate.
  • QIAGEN: Provides QIAstat-Dx molecular POCT systems and sample-prep technologies relevant to rapid infectious disease diagnostics. Adjacent incumbent in the molecular POCT category where Inflammatix's Myrna instrument also competes.
  • bioMérieux (BioFire Diagnostics): BioFire FilmArray panels are a dominant rapid molecular diagnostic for infectious disease in U.S. EDs. While pathogen-detection focused rather than host-response, BioFire is the most entrenched incumbent competing for ED test-menu slots and budgets.
  • Roche Diagnostics: Offers a broad portfolio of hospital and ED diagnostics including Elecsys procalcitonin, cobas molecular systems, and emerging biomarker tests. A large incumbent competing for sepsis-triage test menus in the same hospital customer base.
  • Abbott (Rapid Diagnostics / Alere): i-STAT and Alinity instruments are widely deployed across U.S. EDs for rapid diagnostics including lactate and infectious disease markers. Competes with Inflammatix for ED bench-space real estate and test-menu decisions; Martín Vazquez previously led Abbott Rapid Dx.

Direct peers

  • Cytovale: Commercializes IntelliSep, a FDA-cleared rapid cellular biomarker test for sepsis that delivers results in under 10 minutes from a blood sample. Targets the same ED sepsis-triage workflow as TriVerity with a complementary host-immune-cell measurement approach.
  • T2 Biosystems: Develops T2Bacteria and T2Candida direct-from-blood molecular diagnostics for sepsis-causing pathogens. Operates in the same ED/hospital sepsis-diagnosis segment with an alternative rapid-molecular approach to Inflammatix's host-response test.
  • Immunexpress: Developer of SeptiCyte RAPID, a FDA-cleared host-response gene-expression test for sepsis diagnosis. Directly comparable to Inflammatix's TriVerity in mechanism (host mRNA signatures), clinical use case (ED/ICU sepsis triage), and customer base (hospital labs).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Inflammatix social profiles

Digital presence

Inflammatix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Inflammatix leadership team

Management profile

Number of profiles

Profiles12 records

Inflammatix subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Inflammatix funding detail

Funding detail

Funding overview

Funding rounds8 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Inflammatix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Inflammatix

What does Inflammatix do?

Inflammatix develops and sells the TriVerity Test System, an FDA-cleared rapid blood test that measures 29 host immune response mRNA biomarkers and applies proprietary machine learning classifiers to deliver three actionable scores—likelihood of bacterial infection, viral infection, and severe illness within 7 days—in approximately 30 minutes from a single blood sample. The system consists of the Myrna point-of-care instrument and single-use TriVerity cartridges deployed in hospital emergency departments for triage of patients with suspected acute infection or sepsis.

Is Inflammatix a public or private company?

Inflammatix is a private company. It is classified as venture growth investor backed and is currently operating.

When was Inflammatix founded?

Inflammatix was founded in 2016. It employs 51 to 100 people.

Where is Inflammatix based?

Inflammatix is headquartered in Sunnyvale, United States, in the North America region.

How does Inflammatix make money?

Three revenue lines are on record. Diagnostic Test Sales are the primary driver. The others are licensing Revenue and partnership and Collaboration Revenue.

Who are Inflammatix's main competitors?

Emerging players on record are Prenosis and DxTerity Diagnostics. Broad incumbents are Cepheid (Danaher), QIAGEN, bioMérieux (BioFire Diagnostics), Roche Diagnostics and Abbott (Rapid Diagnostics / Alere). Direct peers are Cytovale, T2 Biosystems and Immunexpress.

Does Inflammatix have an API?

No public API is recorded for Inflammatix.

What industry is Inflammatix in?

Inflammatix's product category is Molecular Diagnostics. Its primary akta.pro industry code is HLAHAOAA, Infectious Disease POCT (Respiratory, STI, HIV, Sepsis), with a secondary code of HLACAGAA, Diagnostic & Triage Decision Support. Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireSepsis Diagnostics Market worth $1.22 billion by 2031 - Exclusive Report by MarketsandMarkets™The sepsis diagnostics market is projected to grow from $0.83 billion in 2026 to $1.22 billion by 2031, a 7.9% CAGR. North America held the largest regional share at 43.2% in 2025, and assays & reagent kits led the product segment. Growth is driven by rising sepsis incidence and demand for rapid diagnostics.SelectScienceRevolutionizing sepsis diagnostics with new breakthrough technologyInflammatix introduced its TriVerity™ Acute Infection and Sepsis Test, powered by the Myrna Instrument, at ADLM 2024 to assess immune responses for diagnosing infections. The test system is currently pending FDA clearance and has not received marketing approval or regulatory clearance in any jurisdiction.Los Angeles TimesHonoree: Jennee DevoreJennee DeVore is recognized for her contributions as the Vice President of Legal at Inflammatix, where she has played a crucial role in navigating legal challenges and launching innovative healthcare products. Over the past two years, she has led significant legal initiatives, including restructuring budgets and implementing in-house manufacturing for a medical diagnostic device. DeVore has also been active in the legal community by creating a subgroup for fractional general counsels within the Women’s General Counsel Network to address the needs of companies in the startup ecosystem.AijournInflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®Inflammatix announced a collaboration with the University of Nebraska Medical Center and the National Quarantine Unit to deploy its TriVerity® host-response diagnostic test in response to a hantavirus outbreak. The test measures the body's immune response through host mRNA markers, providing results in approximately 30 minutes to help clinicians distinguish bacterial from viral infections and predict ICU deterioration risk. The collaboration highlights a shift in infectious disease management from pathogen-specific testing toward real-time immune response assessment when traditional pathogen-detection methods are unavailable or delayed.PR NewswireInflammatix Collaborates with University of Nebraska Medical Center to Support Rapid Response to the Hantavirus Outbreak Using TriVerity®Inflammatix announced a collaboration with the University of Nebraska Medical Center and the National Quarantine Unit to support the response to a hantavirus outbreak using its TriVerity test, which measures host immune response through mRNA to assess bacterial/viral infection likelihood and risk of ICU-level deterioration within seven days. The test delivers results in approximately 30 minutes from a single blood sample, addressing the challenge of hantavirus symptoms that resemble common viral illnesses but can rapidly progress to severe respiratory failure. The collaboration aims to help clinicians better triage patients, optimize isolation protocols, and allocate resources in high-consequence infectious disease settings where pathogen-specific tests may not be widely available.openPR.comIn-Depth Examination of Segments, Industry Trends, and Key Competitors in the Metabolomics Services MarketThe metabolomics services market is projected to reach $5.97 billion by 2030, growing at a CAGR of 14.4%, driven by demand for personalized medicine and precision drug discovery. In June 2025, Bruker Corporation acquired Austria-based Biocrates Life Sciences AG to enhance its multiomics capabilities with Biocrates' mass spectrometry-based metabolomics kits and assays. Additionally, US-based Inflammatix Inc. announced in November 2023 the technical completion of its TriVerity Acute Infection and Sepsis Test System for emergency department use.Stanford University School of EngineeringSaving lives during emergencies with a fast sepsis testInflammatix Inc. received FDA approval in 2025 for TriVerity, a rapid molecular sepsis test developed by Stanford Medicine researchers that delivers results in 30 minutes. The assay utilizes machine learning to analyze immune response markers from blood samples, aiming to improve diagnostic accuracy and clinical decision-making in emergency settings. Early implementations in healthcare systems have reported faster decisions and reduced unnecessary admissions.InflammatixAbout Inflammatix and our teamInflammatix is developing a host-response-based diagnostics pipeline for acute infections, sepsis, and other conditions using bioinformatics and assay development teams. The company initially developed TriVerity, a test for emergency department patients that utilizes patent-pending immune response-based biomarkers exclusively licensed from Stanford University.Chemical & Engineering NewsAll-in-one test could fast-track care for people with possible sepsisThe US Food and Drug Administration has cleared TriVerity, a new diagnostic test developed by Inflammatix to rapidly assess sepsis risk and infection type. A recent study involving over 1,200 adults demonstrated that the test's 29-gene panel is highly sensitive and specific for diagnosing sepsis and predicting ICU needs.PR NewswireInflammatix Announces Three Landmark Publications in Nature Medicine that Redefine Acute Infection and Sepsis Diagnosis and TreatmentInflammatix announced the publication of three pivotal studies in Nature Medicine validating its TriVerity molecular test for sepsis diagnosis, including results from the SEPSIS-SHIELD study involving over 1,200 patients demonstrating high sensitivity and specificity. The test, which has received FDA 510(k) clearance, rapidly distinguishes between bacterial, viral, and non-infectious inflammation while simultaneously predicting illness severity, providing emergency departments with a 30-minute turnaround for triage decisions. The publications also introduced two consensus frameworks—HI-DEF and CTS—that reclassify sepsis into distinct immunological subtypes, potentially enabling precision medicine approaches and targeted drug therapies in intensive care settings.